Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms
CADTH
Record ID 32014000824
English
Authors' recommendations:
One small observational study showed that icatibant appeared effective and safe in the treatment of type III HAE acute attack. However, it is inconclusive and needs to be interpreted with caution due to the important methodological limitations of the body evidence. No evidence for the prophylactic effectiveness of icatibant for patients with type III HAE was found. No evidence on harms associated with long-term use of icatibant is found. Better designed RCTs or larger scale observational studies in Canadian settings are needed to further determine the therapeutic or prophylactic effectiveness and harms of icatibant for patients with type III HAE.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/apr-2014/RC0518%20Icatibant.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bradykinin
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.